Sickle Cell Disease Care Management and Treatment Continuing Education
Chapter No. 2026-6
Email me when SB 844 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track SB 844. By continuing you agree to the Terms and Privacy Policy.
Legislative status
- Introduced
- In Committee
- Reported by Committee
- Floor Vote Scheduled
- Passed One Chamber
- Passed Both Chambers
- Sent to Executive
- Signed into Law
Summary
The bill mandates that any health‑care practitioner registered with the DEA and authorized to prescribe controlled substances must finish a board‑approved two‑hour continuing‑education course. The training covers current prescribing standards, alternatives, non‑drug therapies, emergency opioid antagonists, addiction risks, and pain treatment for sickle‑cell disease. It aims to improve safe prescribing and pain care while tying completion to license renewal.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about SB 844
3 free questions a day, no accountVote
113 yes
0 no
CS passed; YEAS 113, NAYS 0 · Mar 11, 2026
History
- Chapter No. 2026-6
- Approved by Governor
- Signed by Officers and presented to Governor
- Ordered enrolled
- Read 3rd time
- Read 2nd time
- CS passed; YEAS 113, NAYS 0
- Added to Third Reading Calendar
- Temporarily postponed, on 2nd Reading
- Bill added to Special Order Calendar (3/11/2026)
- Added to Second Reading Calendar
- Bill referred to House Calendar
The 12 most recent of 34 recorded actions.
Sponsors
- Appropriations Committee on Health and Human Services · sponsor
- Jones
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when SB 844 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track SB 844 freeOr ask your AI assistant about SB 844 directly:
Add to Claude, ChatGPT or Cursor